ARTICLE | Emerging Company Profile

Two faces of myeloid

How Pionyr intends to enhance the antitumor immune response

October 31, 2017 11:28 PM UTC

Pionyr Immunotherapeutics Inc. has a pipeline of preclinical antibodies that could enable it to selectively deplete immunosuppressive myeloid cells from tumors without harming immune-stimulating myeloid cells.

Myeloid cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) can weaken antitumor immunity and limit efficacy of checkpoint therapies...

BCIQ Company Profiles

Pionyr Immunotherapeutics Inc.